Spark Therapeutics price target raised to $74 from $55 at Leerink. Leerink analyst Joseph Schwartz raised his price target for Spark Therapeutics to $74 from $55 after adjusting his pricing assumptions for the company’s hemophilia gene therapy – SPK-8011 and SPK-9001. The analyst reiterates a Market Perform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.